The company will eliminate its sales force in the U.S. serving the MorphaBond ER product, an extended relief morphine medication. The company will continue to sell the drug, but it will do so without a dedicated sales force.
“We are making this change to focus our resources and energy on our oncology pipeline and our iron business,” an unnamed spokesperson told ROI-NJ. “We are proud and thankful of the effort by our field sales teams and thank them for their dedication to patients and the providers who care for them.”
More articles on pharmacy:
CMS to cover CAR-T therapy nationwide
Colombia fines Pfizer $25K for drug price inflation
Jefferson Healthcare opens retail specialty pharmacy
